Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 2Mouth Neoplasms 2Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Limited Stage 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Gemcitabine 170130-nm albumin-bound paclitaxel 54Albumin-Bound Paclitaxel 42Oxaliplatin 33Fluorouracil 32pembrolizumab 31Capecitabine 30Leucovorin 28Irinotecan 28Radiotherapy 25Nivolumab 22Erlotinib Hydrochloride 21Cisplatin 20Taxes 19Bevacizumab 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiosurgery 11Ipilimumab 11Cyclophosphamide 11Carboplatin 11Drug Therapy 10Biopsy 10Paclitaxel 9Docetaxel 9Cetuximab 9trametinib 8olaparib 8durvalumab 8Sorafenib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Neoplasms × Chemoradiotherapy × Clear all
NCT05417386 2025-11-18

FOLFIRINOX + NIS793 in Pancreatic Cancer

Massachusetts General Hospital

Phase 1 Terminated
4 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡